Frontier to PiT

Output Explorer

Every prompt in the paper, and what each model wrote back.

Name the three firms an acquirer is most likely to buy over the next two years. Every deal in the set was announced after the as-of date.

13 of 129 prompts

Viasat Inc→ Inmarsat PLC · 2021-11-08DoorDash Inc→ Wolt Enterprises Oy · 2021-11-09Take-Two Interactive Software→ Zynga Inc · 2022-01-10NRG Energy Inc→ Vivint Smart Home Inc · 2022-12-06Vistra Corp→ Energy Harbor Corp · 2023-03-06Chevron Corp→ Hess Corp · 2023-10-23AbbVie Inc→ ImmunoGen Inc · 2023-11-30BlackRock Inc→ Global Infrastructure Mgmt LLC · 2024-01-12Advanced Micro Devices Inc→ ZT Group Int'l Inc · 2024-08-19AbbVie Inc→ Stemcentrx Inc · 2016-04-28Quintiles Transnatl Hldg Inc→ IMS Health Holdings Inc · 2016-05-03Gilead Sciences Inc→ Kite Pharma Inc · 2017-08-28Lennar Corp→ CalAtlantic Group Inc · 2017-10-30

Nearby prompts. All 129 M&A targets prompts

PromptAsked as of2022-10-01→ deal announced2023-11-30

What are the top three firms that you predict AbbVie Inc will be interested in acquiring over the next two years?

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question
You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: October 1, 2022
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.
What happened

ImmunoGen Inc — announced 2023-11-30, $10.2B. A response that names the target has used information from after the as-of date.

Models
4 of 4 columns · click a model to add or remove it

Ours

No leak

As AbbVie recently separated from Abbott Laboratories and faces the imminentpatent cliff of its cash cow, HIVBG inhibitor human (Humira/Huigrin-HB), the strategic calculus for management shifts dramatically from 2014 optimism to a more aggressive diversification mindset. With Humira expected to lose exclusivity in the United States around early to mid-2016, AbbVioewill likely spend its record-breaking cash pile—generated almost entirely by Humira in the last few yearsacquire biologics, oncology platforms,or immunology pipelines before the revenue drop-off hits hard.

Based on the portfolio gaps as of December 31, 2015, and the current M&A landscape in biopharmaceuticals, here are the three types of targets AbbVieIncwill most aggressively pursue over the next two years (2016-2017):

1. A Specialized Immunology or Dermatology Biotech with Humira-Type Compounds

Primary Motivation: Abbvioe's entire valuation currently rests on Humira. The patent expiration risk in 2016-202 creates an existential crisis that management is acutely aware of. While Johnson & Johnson, Pfizer, and Actavis are already launching their own biosimiarHumira alternatives, AbbvioeIncwill look to acquire a company that has a next-generation immunomodulator targeting the same indications (Crohn's, rheumatoid arthritis) or expanding into other inflammatory diseases before competitors. Prediction: Abbvioewill target a privately held or NASDAQ-listed biotech that has reached Phase IIb or early Phase III data in an anti-interlukineor novel pathway molecule for autoimmune disease. They will likely be willing to pay a significant premium (high enterprise value multiple) to secure this asset as quickly as possible to build a "Humbrae-proof" portfolio bridge. The firm will likely scour companies emerging from MIT, Harvard, or Boston-based clusters with promising autoimmune platforms.

2. A Oncology Platform Focused on Immuno-Oncotherapy (IO)

Primary Motivation: Abbvioewill realize that their current oncology portfolio is insufficient to replace Humira. While they have some activity in oncology, the field is rapidly shifting toward immune checkpoint inhibitors (like human antibodies). Abbvioewill see that Merck has successfully capitalized on its anti-weevil success (Key Strapp), and will likely attempt to replicate this via acquisition rather than internal discovery alone, which takes too long. Prediction: Abbvioewill look at mid-stage oncology biotehs with promising data in non-Hookerella areas such as lung or skin cancer, specifically those targeting the immune system. They will be interested in firms that possess a robust pipeline of anti-weevers or novel antigen targets that have shown synergy in early data. Abbvioewill are already active in immunology, and oncology offers the next highest growth multiple. A company with a IO platform showing good data could fetch a premium from Abbvioewill as they race to build a "

2,959 characters

Aux 2015

No leakno system prompt

While I don't have access to confidential or non-public information about specific mergers, I can make accurate predictions for top three firms that AbbVie Inc. (or its parent company) may be interested in acquiring over the next two years. These are the three largest publicly traded pharmaceutical companies that offer products that directly compete with AbbVie's core therapeutic areas and where AbbVie has already expressed interest or is a strategic partner.

Let’s break down the top contenders:

  1. Merck & Co.
    – Key Products: HIV/AIDS, allergy, cardiovascular, anti-inflammatory, dermatological, respiratory therapies, osteoporosis treatment – Top Competitors: Novartis, Bayer HealthCare, AstraZeneca, Sanofi-aventis (recently bought by Pfizer), Johnson & Johnson, GlaxoSmithKline, etc. – Since AbbVie has partnered with Merck on several initiatives—especially in diabetes and rheumatology—it makes sense they could consider an acquisition. In 2024 alone, they announced a partnership with Merck on oral immunotherapy for psoriasis and dry eye disease. This shows significant mutual interest and potential value creation opportunities.

  2. Bayer HealthCare AG / Sandoz AG
    – Key Products: Alzheimer’s disease, oncology, autoimmune diseases (like MS), urological disorders (such as prostate cancer), pain management, women’s health – Top Competitors: Roche, Bristol-Myers Squibb, Amgen, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Abbott, etc. – Bayer recently merged with Sandoz, further strengthening their position in high-growth oncology, inflammatory/allergy therapeutics, and central nervous system (CNS) drugs—areas critical for AbbVie. They also have strong offerings in urology, CNS, and orthopedics. – AbbVie is well-positioned with both U.S. and European presence—Bayer’s German HQ provides strong scale and market reach without competing head-to-head with U.S. generics.

  3. Johnson & Johnson (J&J) - Recent Acquisition of Allergan Ltd.
    – Why it matters: J&J is expanding into ophthalmology and dermatology, and currently holds patents on many of AbbVie’s key products. – The deal highlights how J&J is aggressively expanding beyond traditional OTC/OTC generics to focus on more complex therapies like biologics and specialty care. It strengthens their portfolio in important growth categories.

Additionally, there are other notable candidates such as Genzyme Corp., Shire PLC, Valeant Pharma, Teva Pharmaceuticals, Takeda Pharmaceutical Company—but let’s keep these three as the top “intense” candidates based on AbbVie’s current partnerships and recent moves (particularly Merck).

Answer: The top three firms AbbVie Inc. might be most likely to acquire over the next two years include:

  1. Merck & Co. — Focuses on chronic disease, including major drug classes (inflammation/infectious diseases, autoimmune/autoimmunity, neurology, and others), providing complementary strengths for AbbVie’s product pipeline.
  2. Bayer HealthCare AG/Sandoz AG — Offers advanced therapeutic areas such as oncology, inflammatory/allergic, CNS, urology, and women’s health, complementing AbbVie’s strength across these fields.
  3. Johnson & Johnson – Recent Acquisition of Allergan Ltd. — With a growing presence in ocular therapies and specialized biologic products (e.g., Retinoic Acid for diabetic macular edema), this acquisition strengthens AbbVie’s ophthalmology capabilities, particularly in Europe.
3,483 characters

PiT-FT 2015

No leakno system prompt

I can't think of any specific firm, but I'd say the top 3 companies with a market cap of at least $5 billion and revenue exceeding $10 billion.

877 characters

ChronoGPT 2015

No leakno system prompt

AbbVie Inc.

11 characters